Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTIM-76, is a bispecific antibody incorporating highly selective CLDN6 binding arm and CD3 binding single-chain Fv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhanc...
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 15, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Optimeos Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership combines Integral Molecular’s experience in antibody discovery and mRNA immunization with Optimeos’ technology for nanoparticle-based drug delivery systems having nanoparticle-based DNA Therapy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Optimeos Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : SARS-CoV-2 RVPs
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus particles (RVPs), currently over 65 variants, which enables neutralizing antibodies or serum to be assessed in accordance with recent FDA .
Product Name : SARS-CoV-2 RVPs
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 18, 2021
Lead Product(s) : SARS-CoV-2 RVPs
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Optimeos Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will leverage Integral Molecular's industry-leading platform for antibody discovery and include novel targets in cancer and autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Optimeos Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership